GlaxoSmithKline
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Effects Of GW876008 On The Bowel In Patients With Irritable Bowel Syndrome
- Conditions
- Irritable Colon
- First Posted Date
- 2006-10-06
- Last Posted Date
- 2017-08-08
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 10
- Registration Number
- NCT00385099
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
TREXIMA and RELPAX Gastric Scintigraphy Inside and Outside a Migraine
- Conditions
- Migraine Disorders
- Interventions
- Drug: Combination Product (sumatriptan succinate / naproxen sodium)Drug: RELPAX(eletriptan) 40mg Tablet
- First Posted Date
- 2006-10-06
- Last Posted Date
- 2018-02-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 20
- Registration Number
- NCT00385008
- Locations
- 🇺🇸
GSK Investigational Site, Lexington, Kentucky, United States
Effects Of Oral Prednisolone On Bone Metabolism In Patients With Chronic Obstructive Pulmonary Disease
- Conditions
- Chronic Obstructive Pulmonary Disease
- First Posted Date
- 2006-10-06
- Last Posted Date
- 2015-04-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 9
- Registration Number
- NCT00384306
- Locations
- 🇬🇧
GSK Clinical Trials Call Centre, Cambridge, United Kingdom
Evaluate Safety & Immunogenicity of 2 or 3 Doses of GSK HRV Vaccine in Healthy Infants in South Africa
- Conditions
- Infections, Rotavirus
- First Posted Date
- 2006-10-04
- Last Posted Date
- 2016-09-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 472
- Registration Number
- NCT00383903
- Locations
- 🇿🇦
GSK Investigational Site, Sunnyside, Pretoria, South Africa
Comparison of Adjuvanted Hepatitis B Vaccine to Double Dose of Engerix™-B in Pre- /Haemodialysis Patients Aged ≥15 Years
- Conditions
- Hepatitis B
- First Posted Date
- 2006-10-03
- Last Posted Date
- 2006-10-03
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 141
- Registration Number
- NCT00383383
- Locations
- 🇪🇸
GSK Clinical Trials Call Center, Malaga, Spain
Comparison of Adjuvanted Hepatitis B Vaccine to Double Dose of Engerix™-B in Pre- /Haemodialysis Patients Aged ≥15 Years
- Conditions
- Hepatitis B
- First Posted Date
- 2006-10-03
- Last Posted Date
- 2017-03-23
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 120
- Registration Number
- NCT00383591
- Locations
- 🇪🇸
GSK Investigational Site, Malaga, Spain
Comparison of Adjuvanted Hepatitis B Vaccine to Double Dose of Engerix™-B in Pre- /Haemodialysis Patients Aged ≥15 Years
- Conditions
- Hepatitis B
- First Posted Date
- 2006-10-03
- Last Posted Date
- 2016-09-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 165
- Registration Number
- NCT00383227
A Study in Infants to Test Two Preparations (Freeze-dried or Liquid) of the Rotavirus Vaccine (HRV Vaccine).
- Conditions
- Infections, Rotavirus
- First Posted Date
- 2006-10-02
- Last Posted Date
- 2016-11-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1200
- Registration Number
- NCT00382772
- Locations
- 🇫🇮
GSK Investigational Site, Vantaa, Finland
Study Comparing the Immune Response and Safety of Fluarix and Fluzone Influenza Vaccines in Children
- Conditions
- Influenza
- Interventions
- Biological: FluzoneBiological: Fluarix™
- First Posted Date
- 2006-10-02
- Last Posted Date
- 2018-06-08
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 3327
- Registration Number
- NCT00383123
- Locations
- 🇺🇸
GSK Investigational Site, West Jordan, Utah, United States
A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 2 of 2)
- Conditions
- Migraine Disorders
- Interventions
- Drug: PlaceboDrug: Combination Product (sumatriptan succinate/naproxen sodium)
- First Posted Date
- 2006-10-02
- Last Posted Date
- 2017-02-02
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 169
- Registration Number
- NCT00382993
- Locations
- 🇺🇸
GSK Investigational Site, Seattle, Washington, United States